Who should be tested?               

• No biomarker testing is recommended by NCCN with the exception of risk stratification. Genetic counseling and testing if any of the following are indicated:            
  • Early age at diagnosis (<30 years of age)
  • History of other primary cancers in the patient
  • Family or personal history of other cancers known to be associated with a hereditary syndrome:
    • BAP1: RCC, mesothelioma, cutaneous melanoma, cholangiocarcinoma, meningioma
    • BRCA, PALB2: breast, ovarian, or pancreatic cancers

When and what should be tested?

• Upon or before presentation
• Peripheral blood, saliva or buccal mucosa swab
  
  

What tests should be considered?

• NCCN/FDA Approved (uveal melanoma only)
  • Low Risk
    • Disomy 3
    • Gain of function chromosome 6p
    • EIF1AX mutation
  • Medium Risk
    • SF3B1 mutation
  • High risk
    • Monosomy 3
    • Gain of chromosome 8q
    • BAP1
    • PRAME expression
    • MBD4
    • NF-1

Who should be tested?

• Treatment eligible
• Metastatic disease
  
  

When and what should be tested?

• At time of initial diagnosis 
• Recurrence
• Tissue or liquid
  
  

What tests should be considered?

• NCCN/FDA Approved
  •  BRAF*
  • NTRK 1,2,3**
  • TMB
• Emerging biomarkers
  • KIT
  • NRAS
  • ALK
  • ROS1
  • RET

*Included for metastatic and stage III

**Ensure inclusion into the molecularly targeted set of testing recommendations

Who should be tested?

• Treatment eligible
• Unresectable or metastatic disease
  
  

When and what should be tested?

• At time of initial diagnosis 
• Recurrence
• Tissue or liquid (liquid only at recurrent unless another tissue biopsy obtained) 
  
  

What tests should be considered?

• NCCN/FDA Approved
  •  HLA-A *02:01